In this nationwide cohort study investigating patients with coexisting T2DM and ESRD, the pioglitazone group was associated with reduced MACCEs and all-cause mortality when compared to the DPP4-inhibitor group after PSSWs. Here, DPP4 is linked to type 2 diabetes mellitus.